Standard BioTools shares hold over $1 as Nasdaq deadline nears
Standard BioTools shares rose 4.4% to $1.075 early Tuesday, trading above Nasdaq’s $1 minimum bid but still short of the required compliance streak. Volume reached about 1.19 million shares. The company reported Q1 revenue of $21.1 million, up 5%, with lower costs but weak instrument demand. Standard BioTools has until Oct. 19 to regain full compliance with Nasdaq rules.